Kendra Adams - 13 Feb 2026 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
18 Feb 2026, 17:04:45 UTC
Prior SEC filing
19 Sep 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Shagha Russell, Attorney-in-Fact

Key filing fact

Kendra Adams filed Form 4 for C4 Therapeutics, Inc. (CCCC) on 18 Feb 2026.

Key facts

  • This page summarizes Kendra Adams's Form 4 filing for C4 Therapeutics, Inc. (CCCC).
  • 5 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 18 Feb 2026, 17:04.

Change

  • Previous filing in this sequence was filed on 19 Sep 2025.
  • Current net transaction value: -$32,591.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001991929 Primary reporting owner

Adams Kendra

Relationship
Chief Financial Officer
Address
C/O C4 THERAPEUTICS, INC., 490 ARSENAL WAY #120, WATERTOWN
Signature
/s/ Shagha Russell, Attorney-in-Fact
Signature date
18 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CCCC transaction

Common Stock

Award

Transaction value
$0
Shares
+240,000
Change %
+148%
Price
$0.000000
Shares after
402,342
Date
13 Feb 2026
Ownership
Direct
Footnotes
F1
CCCC transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+3,750
Change %
+0.94%
Price
$0.000000
Shares after
402,342
Date
13 Feb 2026
Ownership
Direct
Footnotes
F2
CCCC transaction

Common Stock

Tax liability

Transaction value
$3,521
Shares
-1,863
Change %
-0.46%
Price
$1.89
Shares after
400,479
Date
13 Feb 2026
Ownership
Direct
Footnotes
F3
CCCC transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+30,950
Change %
+8.4%
Price
$0.000000
Shares after
400,479
Date
14 Feb 2026
Ownership
Direct
Footnotes
F2
CCCC transaction

Common Stock

Tax liability

Transaction value
$29,070
Shares
-15,381
Change %
-3.8%
Price
$1.89
Shares after
385,098
Date
14 Feb 2026
Ownership
Direct
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 120,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 120,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.

Footnote F2

Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025.

Footnote F3

Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .